TABLE 1.
Cell source and trial phase of MSC clinical trials for immune/inflammatory lung diseases
| MSC source | Total % | Total no. | No. of clinical trial phases | |||||
|---|---|---|---|---|---|---|---|---|
| ? | 1 | 1&2 | 2 | 2&3 | 3 | |||
| Unspecified | 11.8 | 8 | 0 | 5 | 0 | 2 | 1 | 0 |
| Bone marrow | 32.4 | 22 | 0 | 11 | 2 | 6 | 2 | 1 |
| Umbilical cord | 29.4 | 20 | 3 | 7 | 8 | 2 | 0 | 0 |
| Adipose tissue | 17.6 | 12 | 0 | 3 | 5 | 4 | 0 | 0 |
| Deciduous dental pulp | 2.9 | 2 | 0 | 1 | 1 | 0 | 0 | 0 |
| Placenta | 1.5 | 1 | 0 | 1 | 0 | 0 | 0 | 0 |
| Olfactory mucosa | 1.5 | 1 | 0 | 0 | 1 | 0 | 0 | 0 |
| MSC‐derived products a | 2.9 | 2 | 0 | 2 | 0 | 0 | 0 | 0 |
| Total no. of clinical trial phases | 68 | 3 | 30 | 17 | 14 | 3 | 1 | |
| Total % of clinical trial phases | 4.4 | 44.1 | 25.0 | 20.6 | 4.4 | 1.5 | ||
a
Exosomes or trophic factors collected from conditioned medium.
Abbreviation: MSC, mesenchymal stem cell.